Cargando…
Losartan protects against osteoarthritis by repressing the TGF-β1 signaling pathway via upregulation of PPARγ
OBJECTIVE: Losartan and activation of the peroxisome proliferator-activated receptor-γ (PPARγ) have been previously reported to alleviate the progression of osteoarthritis (OA). However, the nature of the interaction between losartan and PPARγ in OA remains elusive. Therefore, we aimed to investigat...
Autores principales: | Deng, Zhenhan, Chen, Fei, Liu, Yuwei, Wang, Jinping, Lu, Wei, Jiang, Wei, Zhu, Weimin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Chinese Speaking Orthopaedic Society
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8142050/ https://www.ncbi.nlm.nih.gov/pubmed/34094856 http://dx.doi.org/10.1016/j.jot.2021.03.005 |
Ejemplares similares
-
Protective Effect of SIRT1 Activator on the Knee With Osteoarthritis
por: Zhou, Zhenquan, et al.
Publicado: (2021) -
The PPARγ agonist pioglitazone prevents TGF-β induced renal fibrosis by repressing EGR-1 and STAT3
por: Németh, Ágnes, et al.
Publicado: (2019) -
Atorvastatin, Losartan and Captopril Lead to Upregulation of TGF-β, and Downregulation of IL-6 in Coronary Artery Disease and Hypertension
por: Sepehri, Zahra, et al.
Publicado: (2016) -
Pharmacological Repression of PPARγ Promotes Osteogenesis
por: Marciano, David P., et al.
Publicado: (2015) -
Bronchopulmonary Dysplasia: Crosstalk Between PPARγ, WNT/β-Catenin and TGF-β Pathways; The Potential Therapeutic Role of PPARγ Agonists
por: Lecarpentier, Yves, et al.
Publicado: (2019)